Events and Presentations

Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board

Events and Presentations | Investor News | Shareholder Information
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
Press Releases
DateTitle  
06/26/17Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board
DUBLIN, Ireland, June 26, 2017 – Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the appointment of Carrie Bourdow, Senior Vice President and Chief Commercial Officer of Trevena, Inc., to the Company’s Board of Directors. With the completion of the Company’s redom... 
 Printer Friendly Version
06/26/17Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding Common Shares of Nabriva Therapeutics AG and Outstanding American Depositary Shares of Nabriva Therapeutics AG
DUBLIN, Ireland, June 26, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (“Nabriva Therapeutics”) today announced that it has successfully concluded its previously announced tender offer related to the exchange of common shares (“Nabriva AG Common Shares”) of Nabriva Therapeutics AG (“Nabriva AG”) and American depositary shares of Nabriva AG (NASDAQ:NBRV) (“Nabriva AG ADSs”) for ordinary shares (“Nabriva Ireland Shares”) of Nabriva Therapeutics (the “Exchange Offer”).  The Exchange Offer... 
 Printer Friendly Version
06/05/17Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017
VIENNA, Austria and KING OF PRUSSIA, Pa., June 05, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that the Company will webcast its Analyst & Investor Day being held from 9:30 a.m. to 1:30 p.m. ET on June 19, 2017 in New York City. Nabriva will provide an overv... 
 Printer Friendly Version
06/02/17Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin
Four abstracts demonstrate potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa., June 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that data will be presen... 
 Printer Friendly Version
05/23/17Nabriva Commences Previously Announced Tender Offer Related to the Proposed Redomicile of its Holding Company from Austria to Ireland
DUBLIN, Ireland , May 23, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc ("Nabriva Ireland") today commenced the previously announced tender offer related to the exchange of American depositary shares ("Nabriva AG ADSs") and common shares ("Nabriva AG Common Shares") of Nabriva Therapeutics AG (Nasdaq:NBRV) for ordinary shares of Nabriva Ireland (the "Exchange Offer").  Once the Exchange Offer is completed, Nabriva AG will become a subsidiary of Nabriva Ireland, and it is expec... 
 Printer Friendly Version
05/10/17Corrected - Nabriva Therapeutics Reports First Quarter 2017 Financial Results
- Expects top-line data from LEAP 1 CABP Phase 3 trial in third quarter 2017 and from LEAP 2 CABP Phase 3 trial in first quarter 2018Vienna, Austria / King of Prussia, PA, May 12, 2017 – Nabriva Therapeutics AG (NASDAQ: NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and repor... 
 Printer Friendly Version
04/19/17Nabriva Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., April 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Deutsche Bank 42nd Annual Health Ca... 
 Printer Friendly Version
04/17/17Nabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange Offer
VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV) (“Nabriva AG”) announced that its supervisory board and management board approved the relocation of the holding company of Nabriva AG and its subsidiaries (“Nabriva Group”) from Austria to Ireland (the “Redomiciliation Transaction”). The Redomiciliation Transaction will be effected by the exchange of American depositary shares (“Nabriva AG ADSs”) and shares (the “Exchange Offer”) of Nabriva AG for shares ... 
 Printer Friendly Version
04/13/17Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
Nine abstracts support potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa., April 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will present data a... 
 Printer Friendly Version
04/11/17Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia
VIENNA, Austria and KING OF PRUSSIA, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it has completed enrollment in its first lefamulin evaluation against pneumonia (LEAP 1) Phase 3 clinical trial. LEAP 1, which is designed to assess the efficacy ... 
 Printer Friendly Version
03/27/17Nabriva Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., March 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Needham and Company 16th Annual Hea... 
 Printer Friendly Version
03/24/17Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results
VIENNA, Austria and KING OF PRUSSIA, Pa., March 24, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its financial results for the year ended December 31, 2016. “For the last 12 months, we have been executing o... 
 Printer Friendly Version
02/27/17Nabriva Therapeutics to Present at the Cowen and Company 37th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Cowen and Company 37th Annual Health... 
 Printer Friendly Version
02/08/17Nabriva Therapeutics to Participate in Two Investor Conferences in February
VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., Chief Executive Officer of Nabriva Therapeutics, will provide a company overview and business update at the following conferences in February. ... 
 Printer Friendly Version
02/02/17Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia
LEAP 1 top-line efficacy and safety data expected in 3Q17 VIENNA, Austria, and KING OF PRUSSIA, Pa., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that following a blinded interim analysis, an independent committee recommended no sample size adjustment fo... 
 Printer Friendly Version